PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects June 17, 2019 - NASDAQ Companies 0 » View More News for June 17, 2019